<DOC>
	<DOCNO>NCT02310646</DOCNO>
	<brief_summary>To gather insight product attribute affect usability investigate factor think influence patient preference topical anti-psoriatic treatment .</brief_summary>
	<brief_title>Patient Insights Following Use LEO 90100 Aerosol Foam Daivobet® Gel Subjects With Psoriasis Vulgaris</brief_title>
	<detailed_description>An international , multi-centre , prospective , open-label , randomised , 2-arm , cross-over study 14-days daily treatment subject psoriasis vulgaris . To gather insight product attribute affect usability investigate factor think influence patient preference topical anti-psoriatic treatment .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Inclusion : 1 . At Day 1 ( Visit 1 ) , clinical diagnosis psoriasis vulgaris least 6 month duration involve trunk and/or limbs amenable treatment maximum 60 g study medication per week 2 . Psoriasis vulgaris trunk and/or limb ( exclude psoriasis genitals skin fold ) involve 230 % Body Surface Area ( BSA ) Day 1 ( Visit 1 ) 3 . A Physician 's Global Assessment disease severity ( PGA ) least mild trunk and/or limbs Day 1 ( Visit 1 ) 4 . A modified PASI ( mPASI ) score least 2 trunk and/or limbs Day 1 ( Visit 1 ) Exclusion : 1 . Topical antipsoriatic treatment trunk limb within 2 week prior randomisation . 2 . Any previous topical treatment calcipotriol plus betamethasone gel ( Daivobet® gel Xamiol® gel ) . 3 . Psoralen combine Ultraviolet A ( PUVA ) therapy within 4 week prior randomisation . 4 . Ultraviolet B ( UVB ) therapy within 2 week prior randomisation . 5 . Planned excessive exposure area ( ) treat study medication either natural artificial sunlight ( include tan booth , sun lamp etc . ) trial . 6 . Subjects receive treatment nonmarketed drug substance ( i.e . drug yet make available clinical use follow registration ) within 4 weeks/5 halflives ( whichever longer ) prior randomisation . 7 . Previously randomise clinical trial involve LEO 90100 . 8 . Current participation interventional clinical trial . 9 . Previously randomise trial . 10 . Current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . 11 . Subjects follow condition present treatment area : viral ( e.g . herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , ulcer wound . 12 . Other inflammatory skin disorder ( e.g . seborrhoeic dermatitis contact dermatitis ) treatment area may confound evaluation psoriasis . 13 . Known suspected disorder calcium metabolism associate hypercalcaemia . 14 . Known suspect severe renal insufficiency severe hepatic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>